A renowned biotech leader, Jason has over 20 years of experience and demonstrated successes in business development, strategic partnering, M&A, fundraising and establishing and managing significant commercial relationships

Guy is an experienced finance professional with a diverse background in technology leading international manufacturing organisations across medical devices, specialist electronics and speciality chemicals.  Guy has developed a strong skillset in business operations and management, successfully guided businesses through various financial undertakings including fund raising, M&A transactions and exits via trade sale or IPO, while holding key positions in organisations such as Neoss, e2v technologies plc and CIBA Specialty Chemicals (formerly Allied Colloids Group Plc).

Alan has over 20 years of experience in healthcare, specialising in diagnostics at Axis-Shield, Unilever, Unipath and Alere (formerly Inverness Medical) during his career. His roles have involved managing fundamental research, technical scouting, product launch and manufacturing, and on-market support for a number of diagnostic products. Alan has extensive experience of all aspects of the product launch cycle, including taking the Alere HeartCheck product from the patent stage as an inventor to full market launch with CE Marking and ISO Accreditation.

Dr Bea Burke has an extensive background in building successful business through technology translation and strategic partnering, focusing particularly on the application of technologies such as gene editing and next generation sequencing. Working in different sized businesses including Horizon Discovery and Sigma Aldrich, Dr Burke has led across multiple functions including sales, corporate development, strategy, and product management.

Professor Daniel C. Smith has extensive experience in biochemistry, molecular cell biology, and leadership roles within the scientific and business sectors. His career highlights include serving as the Chief Scientific Officer at the UK/Sweden based CDMO Cobra Biologics, both prior to and during its acquisition, first by Cognate Bioservices, and subsequently by Charles River Laboratories. In his current role at That’s Nice, as Chief Science Officer he oversees the scientific direction of the market insights division, supports the strategic marketing function and leads the consultancy arm . Additionally, as the Owner and Principal Consultant of BIOCODEX Limited, he offers strategic support to clients in innovation and technology.

An entrepreneurial and strategic international business leader, Phil joined Gamma Biosciences in 2020 from Cytiva’s Cell and Gene Therapy business. Alongside this, Phil is a board Member of CCRM Enterprises in Toronto Canada and a Board Member of the Foundation for Cell and Gene Medicine. He is also a mentor for the Creative Destruction Lab (CDL) entrepreneurship program, and an advisor to several life sciences companies. Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center and completed his postdoctoral training at the National Cancer Institute in Maryland. 

Carl leads DeciBio’s advanced therapies practice. He brings experience across biopharma, manufacturing / bioprocessing, and supply chain considerations for his clients. He has executed on projects ranging from pipeline prioritization / life cycle management, indication road mapping, growth strategy, and M&A projects across healthcare, life science tools, and pharma (cell and gene therapies). Prior to DeciBio, Carl co-founded and ran Suono Bio, a venture-backed startup where he drove fundraising and executed multiple partnerships and strategic transactions. Carl holds a B.S. from the university of California, Berkeley, and a Ph.D. from MIT where he trained with Professor Robert Langer.

Nick Clarkson has over 20 years’ experience in research and development in cell and gene therapy and immunology. He is currently Vice President and Head of Process Development at OXB which is a world leading viral vector CDMO.  He has held senior leadership roles in innovation and analytical development. This gives him a breadth of experience spanning basic research and development in viral vector manufacturing platforms, through to scale up for GMP manufacturing and validation for commercial products.